Why Pfizer Was a Surprising Loser in 2020 but Could Win Big Time in 2021

1 min read

In theory, 2020 should have been a great year for Pfizer (NYSE: PFE) shareholders. The big drugmaker, along with its German partner BioNTech (NASDAQ: BNTX), became the first to secure U.S. emergency use authorization for a coronavirus vaccine. Pfizer also wrapped up a long-awaited deal to spin off its Upjohn unit, paving the way for stronger growth.

But theories don’t always fare so well in the real world. Despite its major achievements last year, Pfizer’s shares actually slipped nearly 1%. Pfizer was a surprising loser in 2020. However, the pharma stock could win big time in 2021. 

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

1 FAANG Stock to Buy and 1 to Avoid in 2021

Next Story

This ETF Could Turn Your $600 Stimulus Check Into $3,768

Latest from Blog